JP2012515778A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012515778A5 JP2012515778A5 JP2011548074A JP2011548074A JP2012515778A5 JP 2012515778 A5 JP2012515778 A5 JP 2012515778A5 JP 2011548074 A JP2011548074 A JP 2011548074A JP 2011548074 A JP2011548074 A JP 2011548074A JP 2012515778 A5 JP2012515778 A5 JP 2012515778A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- variant
- seq
- cells
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000000588 Interleukin-2 Human genes 0.000 claims description 36
- 108010002350 Interleukin-2 Proteins 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 23
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 102100027581 Forkhead box protein P3 Human genes 0.000 claims description 18
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims description 18
- 229920001184 polypeptide Polymers 0.000 claims description 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 108010029477 STAT5 Transcription Factor Proteins 0.000 claims description 16
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 claims description 16
- 230000035772 mutation Effects 0.000 claims description 16
- 230000026731 phosphorylation Effects 0.000 claims description 16
- 238000006366 phosphorylation reaction Methods 0.000 claims description 16
- 210000003289 regulatory T cell Anatomy 0.000 claims description 13
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims description 2
- 102220494399 Signal transducer and activator of transcription 5A_Y31H_mutation Human genes 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 102220274636 rs144712084 Human genes 0.000 claims description 2
- 102220050130 rs187015338 Human genes 0.000 claims description 2
- 102220044643 rs587781450 Human genes 0.000 claims description 2
- 102200053439 rs72466487 Human genes 0.000 claims description 2
- 102220148530 rs886061344 Human genes 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 22
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14611109P | 2009-01-21 | 2009-01-21 | |
| US61/146,111 | 2009-01-21 | ||
| PCT/US2010/021519 WO2010085495A1 (en) | 2009-01-21 | 2010-01-20 | Compositions and methods of treating inflammatory and autoimmune diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014083388A Division JP2014133756A (ja) | 2009-01-21 | 2014-04-15 | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012515778A JP2012515778A (ja) | 2012-07-12 |
| JP2012515778A5 true JP2012515778A5 (enExample) | 2013-02-14 |
| JP5766124B2 JP5766124B2 (ja) | 2015-08-19 |
Family
ID=42356180
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011548074A Active JP5766124B2 (ja) | 2009-01-21 | 2010-01-20 | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
| JP2014083388A Withdrawn JP2014133756A (ja) | 2009-01-21 | 2014-04-15 | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
| JP2016092985A Withdrawn JP2016138140A (ja) | 2009-01-21 | 2016-05-06 | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
| JP2018031926A Withdrawn JP2018087244A (ja) | 2009-01-21 | 2018-02-26 | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
| JP2019191112A Withdrawn JP2020023550A (ja) | 2009-01-21 | 2019-10-18 | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
| JP2021143804A Withdrawn JP2021185191A (ja) | 2009-01-21 | 2021-09-03 | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
| JP2024085664A Pending JP2024105721A (ja) | 2009-01-21 | 2024-05-27 | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014083388A Withdrawn JP2014133756A (ja) | 2009-01-21 | 2014-04-15 | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
| JP2016092985A Withdrawn JP2016138140A (ja) | 2009-01-21 | 2016-05-06 | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
| JP2018031926A Withdrawn JP2018087244A (ja) | 2009-01-21 | 2018-02-26 | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
| JP2019191112A Withdrawn JP2020023550A (ja) | 2009-01-21 | 2019-10-18 | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
| JP2021143804A Withdrawn JP2021185191A (ja) | 2009-01-21 | 2021-09-03 | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
| JP2024085664A Pending JP2024105721A (ja) | 2009-01-21 | 2024-05-27 | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US20110274650A1 (enExample) |
| EP (1) | EP2382228B1 (enExample) |
| JP (7) | JP5766124B2 (enExample) |
| AU (1) | AU2010206840B2 (enExample) |
| CA (1) | CA2749539C (enExample) |
| ES (1) | ES2825173T3 (enExample) |
| MX (1) | MX2011007647A (enExample) |
| WO (1) | WO2010085495A1 (enExample) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011007647A (es) | 2009-01-21 | 2011-09-01 | Amgen Inc | Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes. |
| CU23923B1 (es) * | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| WO2012088446A1 (en) | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| LT3075745T (lt) * | 2011-02-10 | 2018-11-26 | Roche Glycart Ag | Mutavę interleukino-2 polipeptidai |
| DK3443979T3 (da) | 2011-03-11 | 2020-08-24 | Assist Publique - Hôpitaux De Paris | Il-2-doseringsplan til behandling af systemisk lupus erythematosus |
| BR112013023151A2 (pt) | 2011-03-11 | 2020-09-15 | Assistance Publique - Hôpitaux De Paris | interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| US9481866B2 (en) * | 2011-12-16 | 2016-11-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T cell populations enriched for stable regulatory T-cells |
| US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| US9546203B2 (en) | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
| CN105722860A (zh) | 2013-09-24 | 2016-06-29 | 梅迪塞纳医疗股份有限公司 | 白介素-2融合蛋白及其应用 |
| PE20161324A1 (es) * | 2014-02-06 | 2016-11-25 | Hoffmann La Roche | Proteinas de fusion de interleucina-2 y usos de las mismas |
| JP6592505B2 (ja) * | 2014-04-24 | 2019-10-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト |
| DK3172227T3 (da) * | 2014-07-21 | 2019-12-02 | Delinia Inc | Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme |
| EP3482766B1 (en) | 2014-08-11 | 2020-05-20 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| PE20180132A1 (es) * | 2015-04-10 | 2018-01-18 | Amgen Inc | Muteinas de interleuquina 2 para la expansion de celulas t regulatorias |
| IL304950A (en) | 2015-04-10 | 2023-10-01 | Amgen Inc | Interleukin for the expansion of myotonic control T-2 cells |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| KR20240115933A (ko) | 2016-05-04 | 2024-07-26 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| CN109475628A (zh) | 2016-05-18 | 2019-03-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| CN110167957A (zh) | 2016-11-08 | 2019-08-23 | 德里尼亚公司 | 用于治疗自身免疫疾病的il-2变体 |
| AU2017379900B2 (en) | 2016-12-22 | 2024-12-05 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| WO2018129474A1 (en) | 2017-01-09 | 2018-07-12 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| EP3596118B1 (en) | 2017-03-15 | 2024-08-21 | Cue Biopharma, Inc. | Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer |
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| EP3641814A4 (en) | 2017-06-19 | 2021-06-23 | Medicenna Therapeutics Inc. | USES AND METHODS FOR IL-2 SUPERAGONISTS AND AGONISTS AND FUSIONS THEREOF |
| CA3069321A1 (en) | 2017-07-11 | 2019-01-17 | Synthorx, Inc. | Incorporation of unnatural nucleotides and methods thereof |
| US20200181220A1 (en) | 2017-08-03 | 2020-06-11 | Synthorx, Inc. | Cytokine conjugates for the treatment of proliferative and infectious diseases |
| JP2021500855A (ja) * | 2017-09-07 | 2021-01-14 | キュー バイオファーマ， インコーポレイテッド | 抗原提示ポリペプチドおよびその使用方法 |
| WO2019104092A1 (en) | 2017-11-21 | 2019-05-31 | The Board Of Trustees Of The Leland Stanford Junior University | Partial agonists of interleukin-2 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| MX2020006322A (es) | 2017-12-19 | 2020-09-18 | Xencor Inc | Proteinas de fusion il-2 fc modificadas. |
| AU2018394189B2 (en) * | 2017-12-27 | 2023-12-21 | Kyowa Kirin Co., Ltd. | IL-2 variant |
| WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| EP3752178A1 (en) | 2018-02-16 | 2020-12-23 | Iltoo Pharma | Use of interleukin 2 for treating sjögren's syndrome |
| CA3115461A1 (en) | 2018-03-09 | 2019-09-12 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
| US11359000B2 (en) | 2018-03-28 | 2022-06-14 | Bristol-Myers Squibb Company | Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use |
| WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
| US12459980B2 (en) | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| US12403181B2 (en) | 2018-08-13 | 2025-09-02 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| MA54195A (fr) | 2018-11-08 | 2022-02-16 | Synthorx Inc | Conjugués d'interleukine 10 et leurs utilisations |
| JP7543269B2 (ja) | 2018-12-21 | 2024-09-02 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | ヒトインターロイキン２の変異体またはその誘導体 |
| US20200246467A1 (en) | 2019-02-06 | 2020-08-06 | Synthorx, Inc. | Il-2 conjugates and methods of use thereof |
| KR20210128443A (ko) | 2019-02-15 | 2021-10-26 | 인테그럴 몰큘러 인코포레이티드 | 클라우딘 6 항체 및 이의 용도 |
| CA3129317A1 (en) | 2019-02-15 | 2020-08-20 | Integral Molecular, Inc. | Antibodies comprising a common light chain and uses thereof |
| US20220193198A1 (en) * | 2019-03-29 | 2022-06-23 | Institut Curie | Interleukin-2 Variants with Modified Biological Activity |
| EP3972992A4 (en) | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | MADCAM TARGETED IMMUNOTLERANCE |
| AU2020287373A1 (en) * | 2019-06-05 | 2022-01-06 | Asher Biotherapeutics, Inc. | Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function |
| WO2020252264A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| PH12022550326A1 (en) | 2019-08-13 | 2023-03-13 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells |
| AU2020329933A1 (en) * | 2019-08-15 | 2022-03-24 | Cytimm Therapeutics, Inc. | Modified interleukin 2 (IL-2) polypeptides, conjugates and uses thereof |
| CN114555632A (zh) | 2019-08-23 | 2022-05-27 | 新索思股份有限公司 | Il-15缀合物及其用途 |
| CA3150082A1 (en) | 2019-09-10 | 2021-03-18 | Jerod PTACIN | Il-2 conjugates and methods of use to treat autoimmune diseases |
| TW202128961A (zh) | 2019-11-20 | 2021-08-01 | 美商安維塔生物科學股份有限公司 | 細胞激素融合蛋白及其醫藥組合物及治療應用 |
| KR20220139293A (ko) | 2019-12-12 | 2022-10-14 | 일투 파마 | 인터류킨 2 키메라 구축물 |
| JP7755581B2 (ja) | 2019-12-17 | 2025-10-16 | アムジエン・インコーポレーテツド | 治療における使用のためのデュアルインターロイキン－２／ｔｎｆ受容体アゴニスト |
| US20210188934A1 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
| WO2021140416A2 (en) | 2020-01-10 | 2021-07-15 | Bright Peak Therapeutics Ag | Modified il-2 polypeptides and uses thereof |
| US11491205B2 (en) | 2020-01-14 | 2022-11-08 | Synthekine, Inc. | Biased IL2 muteins methods and compositions |
| AU2021207661A1 (en) * | 2020-01-14 | 2022-07-21 | Synthekine, Inc. | IL2 muteins |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| KR20230004682A (ko) | 2020-04-22 | 2023-01-06 | 머크 샤프 앤드 돔 엘엘씨 | 인터류킨-2 수용체 베타 감마c 이량체에 대해 편향되고 비펩티드성 수용성 중합체에 접합된 인간 인터류킨-2 접합체 |
| US11897930B2 (en) | 2020-04-28 | 2024-02-13 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
| EP4149534A4 (en) | 2020-05-12 | 2024-09-04 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF |
| IL298642A (en) | 2020-06-03 | 2023-01-01 | Ascendis Pharma Oncology Div A/S | il-2 sequences and uses thereof |
| US20220033784A1 (en) * | 2020-07-14 | 2022-02-03 | Pfizer Inc. | Recombinant vaccinia virus |
| JP2023540701A (ja) * | 2020-08-28 | 2023-09-26 | アセンディス ファーマ オンコロジー ディヴィジョン エー／エス | グリコシル化ｉｌ－２タンパク質及びその使用 |
| WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
| IL302276A (en) | 2020-10-23 | 2023-06-01 | Asher Biotherapeutics Inc | Fusions with cd8 antigen binding molecules for modulating immune cell function |
| WO2022094275A1 (en) | 2020-10-29 | 2022-05-05 | Bristol-Myers Squibb Company | Fusion proteins for the treatment of disease |
| CN112279906B (zh) * | 2020-10-30 | 2022-09-20 | 浙江新码生物医药有限公司 | 人白细胞介素2-聚乙二醇偶联物及其制备方法与应用 |
| TW202227123A (zh) | 2020-11-13 | 2022-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種包含人白細胞介素２變體或其衍生物的醫藥組成物及其用途 |
| EP4255466A1 (en) * | 2020-12-04 | 2023-10-11 | Visterra, Inc. | Methods of using interleukin-2 agents |
| CN116854802A (zh) * | 2021-04-13 | 2023-10-10 | 苏州复融生物技术有限公司 | 白介素2突变体及其应用 |
| US20230201364A1 (en) | 2021-07-09 | 2023-06-29 | Bright Peak Therapeutics Ag | Antibody conjugates and manufacture thereof |
| CA3222357A1 (en) | 2021-07-09 | 2023-01-12 | Bertolt Kreft | Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases |
| JP7618848B2 (ja) | 2021-07-30 | 2025-01-21 | ドラコターピン バイオメディスン エルエルシー | ヒトインターロイキン－２変異体およびその使用 |
| MX2024004291A (es) | 2021-10-06 | 2024-06-28 | Iltoo Pharma | Construcciones quiméricas de interleucina 2 con especificidad de direccionamiento a tejidos inflamados. |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| CA3265946A1 (en) | 2022-09-12 | 2024-03-21 | Univ Sorbonne | INTERLEUKIN-2 FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS |
| IL319951A (en) | 2022-11-30 | 2025-05-01 | Integral Molecular Inc | Antibodies targeting claudin 6, including its bispecific formats |
| AU2024207151A1 (en) | 2023-01-09 | 2025-06-19 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| WO2025221954A1 (en) | 2024-04-17 | 2025-10-23 | Visterra, Inc. | Use of il-2 variant for treating kidney transplant rejection |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4470461A (en) | 1982-09-30 | 1984-09-11 | Phillips Petroleum Company | Organic nitro compounds as cosurfactants in enhanced oil recovery processes |
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| EP0262802A3 (en) | 1986-09-01 | 1990-01-31 | Takeda Chemical Industries, Ltd. | Medicament for the treatment or improvement of rheumatoid arthritis or systemic lupus erythematosus |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5466447A (en) | 1988-06-29 | 1995-11-14 | Amgen Inc. | Method for treating psoriasis |
| JPH03500415A (ja) | 1988-07-05 | 1991-01-31 | アムジエン・インコーポレーテツド | インターロイキン２類似体 |
| CA2062582C (en) | 1991-03-27 | 1996-03-26 | Tse-Wen Chang | Methods and substances for recruiting therapeutic agents to solid tissues |
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6348192B1 (en) | 1999-05-11 | 2002-02-19 | Bayer Corporation | Interleukin-2 mutein expressed from mammalian cells |
| ATE336514T1 (de) | 2000-02-11 | 2006-09-15 | Merck Patent Gmbh | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen |
| WO2003015697A2 (en) | 2001-08-13 | 2003-02-27 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
| PT1454138E (pt) | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| AR043504A1 (es) * | 2003-03-17 | 2005-08-03 | Novartis Ag | Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias |
| WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| AU2005227263A1 (en) | 2004-03-05 | 2005-10-06 | Novartis Vaccines And Diagnostics, Inc. | In vitro test system for predicting patient tolerability of therapeutic agents |
| AU2006232374B2 (en) * | 2005-04-01 | 2011-08-25 | University Of Southern California | Preventing rejection of transplanted tissue using regulatory T cells |
| AU2007214426A1 (en) | 2006-02-16 | 2007-08-23 | Nascent Biologics, Inc. | Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject |
| WO2007100770A2 (en) | 2006-02-28 | 2007-09-07 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
| CA2656700A1 (en) | 2006-07-06 | 2008-01-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
| JPWO2008004373A1 (ja) | 2006-07-06 | 2009-12-03 | 三菱電機株式会社 | ナビゲーション装置 |
| GB0623539D0 (en) | 2006-11-24 | 2007-01-03 | Avidex Ltd | Polypeptides |
| AU2008219666A1 (en) | 2007-02-27 | 2008-09-04 | Genentech, Inc. | Antagonist OX40 antibodies and their use in the treatment of inflammatory and autoimmune diseases |
| EP2139509A2 (en) | 2007-03-15 | 2010-01-06 | Biogen Idec MA, Inc. | Treatment of autoimmune disorders |
| WO2009061853A2 (en) | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
| PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
| DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
| WO2010017220A1 (en) | 2008-08-04 | 2010-02-11 | The Trustees Of The University Of Pennsylvania | Methods for expanding regulatory t-cells |
| US20110200534A1 (en) | 2008-08-21 | 2011-08-18 | Industry-Academic Cooperation Foundation, Yonsei U | T1-T2 Dual Modal MRI Contrast Agents |
| MX2011007647A (es) * | 2009-01-21 | 2011-09-01 | Amgen Inc | Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes. |
| DK3443979T3 (da) | 2011-03-11 | 2020-08-24 | Assist Publique - Hôpitaux De Paris | Il-2-doseringsplan til behandling af systemisk lupus erythematosus |
| MX348071B (es) | 2011-03-16 | 2017-05-26 | Amgen Inc | Variantes de fc. |
-
2010
- 2010-01-20 MX MX2011007647A patent/MX2011007647A/es active IP Right Grant
- 2010-01-20 US US13/145,537 patent/US20110274650A1/en not_active Abandoned
- 2010-01-20 WO PCT/US2010/021519 patent/WO2010085495A1/en not_active Ceased
- 2010-01-20 AU AU2010206840A patent/AU2010206840B2/en active Active
- 2010-01-20 CA CA2749539A patent/CA2749539C/en active Active
- 2010-01-20 JP JP2011548074A patent/JP5766124B2/ja active Active
- 2010-01-20 ES ES10733814T patent/ES2825173T3/es active Active
- 2010-01-20 EP EP10733814.7A patent/EP2382228B1/en active Active
-
2012
- 2012-11-08 US US13/672,417 patent/US9732134B2/en active Active
-
2014
- 2014-04-15 JP JP2014083388A patent/JP2014133756A/ja not_active Withdrawn
-
2016
- 2016-05-06 JP JP2016092985A patent/JP2016138140A/ja not_active Withdrawn
-
2017
- 2017-07-13 US US15/649,520 patent/US11560415B2/en active Active
-
2018
- 2018-02-26 JP JP2018031926A patent/JP2018087244A/ja not_active Withdrawn
-
2019
- 2019-10-18 JP JP2019191112A patent/JP2020023550A/ja not_active Withdrawn
-
2021
- 2021-09-03 JP JP2021143804A patent/JP2021185191A/ja not_active Withdrawn
-
2022
- 2022-12-20 US US18/068,970 patent/US12297248B2/en active Active
-
2024
- 2024-05-27 JP JP2024085664A patent/JP2024105721A/ja active Pending
-
2025
- 2025-01-17 US US19/028,861 patent/US20250270271A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012515778A5 (enExample) | ||
| RU2506274C2 (ru) | Способы скрининга с применением g-белок сопряженных рецепторов и родственных композиций | |
| ATE540973T1 (de) | Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung | |
| TW201129379A (en) | Anti-Orai1 antigen binding proteins and uses thereof | |
| CL2018000537A1 (es) | Anticuerpo anti-factor d del complemento; polinucleótido codificante; vector que comprende dicho polinucleótido; célula húesped que comprende dicho vector; método de fabricación de anticuerpo; composición farmacéutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares (divisional de cl 1001-2009). | |
| JP2010516290A5 (enExample) | ||
| JP2012505837A5 (enExample) | ||
| RU2013126581A (ru) | Мутанты стрептокиназы и их ковалентно модифицированные формы | |
| CA2567177A1 (en) | Genetically engineered cells for therapeutic applications | |
| EA200800368A1 (ru) | Гликозилированный il-7, получение и применение | |
| NZ602471A (en) | Antagonists of activin-actriia and uses for increasing red blood cell levels | |
| JP2008536483A5 (enExample) | ||
| JP2012512910A5 (enExample) | ||
| EP2390265A3 (en) | Insulinotropic peptide derivative wherein its N-terminal amino acid is modified | |
| JP2011505414A5 (enExample) | ||
| JP2012512911A5 (enExample) | ||
| CN104395391A (zh) | 双重衍生化的壳聚糖纳米粒子以及制造和使用其用于体内基因转移的方法 | |
| TW200944226A (en) | Biologically active peptides | |
| CN104395338A (zh) | 人胰岛淀粉样多肽类似物 | |
| JPWO2019156137A5 (enExample) | ||
| JP2015522264A5 (enExample) | ||
| JP2010518810A5 (enExample) | ||
| ES2685987T3 (es) | Análogos de péptidos gip | |
| JP2012514466A5 (enExample) | ||
| RU2016107873A (ru) | Пептиды |